Dishman Carbogen Amcis is a global outsourcing partner for drug innovators - it takes a molecule from a scientist’s bench through to commercial manufacturing, handling the chemistry, the safety testing and the factory scale-up so its clients can focus on discovering new medicines. The company was born in 1983 making niche chemical catalysts, but its defining move was the 2006 acquisition of Swiss-based CARBOGEN AMCIS, which transformed it from a bulk-intermediates maker into a fully integrated Contract Development and Manufacturing Organization (CDMO) straddling India and Europe. Everything the business does flows from a single recurring approach: it invests early in complex, hard-to-replicate capabilities - high-potency handling, chromatography at production scale, antibody-drug conjugate (ADC) manufacturing - and then locks in long-term partnerships with innovator pharma companies through co-investment agreements that make it their preferred factory for decades.
Business segments
Two engines that feed each other - a CDMO business that develops and makes other companies’ drugs, and a Marketable Molecules business that sells its own portfolio of vitamins, specialty chemicals and generic APIs, built on the same manufacturing backbone.
1. CDMO: the outsourced R&D and factory floor for the world’s drug innovators
The company earns revenue by developing, scaling up and manufacturing drug substances and drug products for pharmaceutical companies, with a particular grip on highly potent, oncology-focused molecules that few competitors can handle safely.
- Paid for development hours and commercial supply - revenue comes from project-based R&D work (pre-clinical through Phase II) and from long-term commercial manufacturing contracts once a drug is approved; later-stage Phase III and commercial work carries higher margins than early-phase development.
- A two-continent factory network that splits the work - CARBOGEN AMCIS in Europe provides the high-science process R&D, clinical trial supply and niche commercial manufacturing, while Dishman India delivers large-scale, lower-cost commercial production; the first API has already been transferred from Europe to India to improve its cost base.
- High-potency is the moat - the company has 20 years of experience handling highly potent APIs (HiPo) down to below 10 nanograms per cubic metre occupational exposure, with dedicated facilities in Switzerland, India and China; it is among the first movers globally in this space, which creates a natural barrier for competitors.
- ADC capability covers three of the four steps in-house - it makes the toxic payload and linker, performs the conjugation to attach them to an antibody, and then does the sterile fill-finish into injectable vials; the company has handled ADC projects since 2005 and now offers this as an integrated package from a single supplier.
- Customers co-invest in the factories - the company has signed co-investment agreements worth more than CHF 15 million with a Japanese innovator to build dedicated ADC linker capacity at its Swiss site, and over CHF 4 million with a European client to expand another facility; these partnerships span more than a decade and make the relationship deeply sticky.
2. Marketable Molecules: a portfolio of proprietary vitamins, chemicals and generics
This segment sells the company’s own products - led by Vitamin D and its analogues - into pharmaceutical, nutraceutical and industrial markets, using the same Indian and European factories that serve the CDMO business.
- Vitamin D from sheep’s wool, not fish - the business extracts cholesterol from wool grease as the starting material for Vitamin D3, making it a vegan-compatible source; the Dutch facility in Veenendaal has over 70 years of experience in this process, and a second fully integrated manufacturing unit in India can produce 1,000 metric tonnes annually.
- Shifted up the value chain into high-margin analogues - the company has moved from basic Vitamin D products into more complex, patent-protected analogues, including one recognised by the European Patent Office as a novel supplement for obesity patients who cannot absorb standard Vitamin D.
- Specialty chemicals with a 40-year pedigree - the business still makes the quaternary ammonium compounds and phase transfer catalysts it was founded on, now supplied under GMP conditions from the Naroda plant in India, with local stocks held in Europe and the US for quick delivery.
- Niche generics and disinfectants fill out the catalogue - the portfolio includes imaging reagents with regulatory filings in place, and a range of antiseptics based on Chlorhexidine Gluconate and Octenidine, sold into healthcare settings.
Group structure and partners
The company is an Indian-listed entity that operates through a cluster of wholly owned CARBOGEN AMCIS subsidiaries across Europe and China, with strategic co-investment deals that tie its factories to specific innovator clients for a decade or more.
- The flagship listed company, Dishman Carbogen Amcis Ltd, is headquartered in Ahmedabad and listed on the BSE and NSE, with promoters holding just over 59%.
- CARBOGEN AMCIS AG in Switzerland is the principal operating subsidiary, with sites in Bubendorf, Neuland, Aarau and Vionnaz; further wholly owned subsidiaries run the UK (Manchester), France (Saint-Beauzire drug product facility), China (Shanghai) and Netherlands (Veenendaal) operations.
- A Japanese innovator has entered into a second co-investment agreement for CHF 25 million to expand ADC linker capacity at the Bubendorf site.
- A European client has co-invested over CHF 4 million to expand additional process capabilities and capacities, building on an earlier CHF 6 million investment, in a collaboration that has now run for more than 10 years.
- In October 2025, CARBOGEN AMCIS formed a strategic alliance with Celonic Group to offer a fully integrated ADC platform, combining Celonic’s biologics with its own payload synthesis, conjugation and sterile fill-finish capabilities.